Introduction {#S0001}
============

Primary spinal epidural lymphoma (PSEL) is an entity of lymphomas located in epidural without any other recognizable sites of lymphomas at diagnosis.[@CIT0001] An epidural location for lymphoma is observed in 0.1--6.5% of all the lymphomas;[@CIT0001] thus, it is challenging at diagnosis and may easily be misdiagnosed. Here, we presented a case of primary spinal epidural DLBCL with paraplegia as the first manifestation.

Case presentation {#S0002}
=================

A 39-year-old man was admitted to our hospital on December 23, 2015, with back pain, numbness and weakness of lower limbs for 2 months. Thoracic disc herniation was considered in local hospital 2 months ago; however, conservative treatment did not work. Moreover, the disease quickly progressed to paraplegia on December 24, 2015. The neurologic examination demonstrated a minor motor impairment of lower limbs and reflexes were hyperactive. Anal sphincter tone was without damage, negative Hoffman, Trömner and Babinski's sign. He presented a sensory level of hypoesthesia and loss of thermalgesia at T7. T-SPOT.TB was positive. The enhanced magnetic resonance imaging (MRI) of thoracic vertebra on December 24, 2015 ([Figure 1](#F0001){ref-type="fig"}), suggested that thoracic 7 vertebral body, the thoracic 7 and 8 vertebral body accessory tuberculosis was considered, accompanied by intraspinal abscess formation. He was misdiagnosed with thoracic tuberculosis. Posterior pedicle screw fixation + spinal canal decompression + lesion clearance + bone grafting and fusion was performed on December 25, 2015. Surgical pathology suggested DLBCL. The immunohistochemical ([Figure 2](#F0002){ref-type="fig"}) hinted tumor cells CD20 (+), CD79a (+), PAX-5 (+), Bob-1 (+), Oct2 (+), CD10 (+), BcL-2 (+), Bcl-6 (+), CD15 (-), CD30 (+), CD23 (+), CD21 (+), MUM1 (+) and Ki-67 (+ \>30%). Reactive cells CD3 (+), CD5 (+), CD43 (+), CD45RO (+); CDla (-), ALK (-), EMA (-), TdT (-), CD117 (-), HMB45 (-), S100 (-), CD31 (-), CK (-) and EBER (-). 18F-fluorodeoxyglucose (18F-FDG)-positron emission tomography/computed tomography (PET/CT) imaging on January 14, 2016 ([Figure 3A](#F0003){ref-type="fig"} and [B](#F0003){ref-type="fig"}) showed T8--10 vertebral body, retroperitoneal enlarged lymph nodes, left iliac bone and left femur with increased uptake of 18F-FDG. Based on these, systemic chemotherapy with rituximab + CHOPE (R-CHOPE) was determined as an appropriate treatment for the patient since January 20, 2016. After four cycles of chemotherapy with R-CHOPE, PET/CT on May 12, 2016 ([Figure 3C](#F0003){ref-type="fig"} and [D](#F0003){ref-type="fig"}) suggested that, compared with PET/CT on January 14, 2016, 18F-FDG uptake concentration in the original area all disappeared, suggesting that the tumor was relieved. Then, the strength of both lower extremities gradually recovered, and he could walk. After another two cycles of chemotherapy with R-ECHOP on May 14, 2016, and on June 11, 2016, respectively, the patient went to follow-up time. During the nearly 2-year follow-up, the disease still has no relapse.Figure 1Epidural soft tissue mass located in the spinal canal outside the back of the dura mater at T4--T9 level, dura mater and spinal cord significantly compressed forward, and the narrowed spinal canal. (**A**) T1WI at the position of sagittalia, low signal, (**B**) Sagittal postcontrast T1-weighted image of the thoracic spine reveals enhancing sheet-like lesion in the posterior epidural region compressing the thoracic cord. Shown by red arrow mark, (**C**) T2WI at the position of sagittalia, high signal, (**D**) T2WI at coronal section, high signal, (**E**) T1WI contrast enhancing at transverse section, high signal at T7 level obviously enhanced, (**F**) T2WI at transverse section, high signal at T7 level. No abnormal changes were observed in the intervertebral disc.Figure 2(**A**) Hematoxylin and eosin stain (×40), (**B**) CD20 (+) (×20), (**C**) CD10 (+) (×20), (**D**) BCL-2 (+) (×20), (**E**) BCL-6 (+) (×20), (**F**) C-MYC (+) (×20).Figure 3(**A** and **B**) PET/CT on January 14, 2016, showed T8--10 vertebral body, retroperitoneal enlarged lymph nodes, left iliac bone and left femur with increased uptake of 18F-FDG. (**C** and **D**) PET/CT on May 12, 2016, showed that18F-FDG uptake concentration in the original area all disappeared.

Ethical approval was not necessary for the case report. The patient has consented for the publication of the present case report.

Discussion {#S0003}
==========

In this case, the patient was misdiagnosed as thoracic disc herniation and thoracic tuberculosis successively ([Figure 4](#F0004){ref-type="fig"}). In the previous reported study,[@CIT0002] the overall specificity and sensitivity of the T-SPOT.TB were 92.83% and 83.67%, respectively. Patients with cured tuberculosis tended to induce false-positive results. In this case, T-SPOT.TB was false-positive.Figure 4The process of therapy.

PSEL usually occurs in 40--50 years old, and the male-female ratio is 1.6:1. The 3-year overall survival was 81.1%, and disease-free survival rate was 46.3%.[@CIT0003] The origin of PSEL is thought to be derived from lymphatic tissue along the venous plexus in the epidural space or the paravertebral lymphoid rests or the vertebral body, which later extends to the epidural space.[@CIT0004] The most common presenting symptoms reported included lower limb weakness, localized back pain, and bladder dysfunction. The symptoms and signs of the disease depend on the location and size of the tumor. The onset is usually subacute, ranging from days to weeks. The clinical symptoms are divided into two stages: the first stage is the prodromal stage, which is characterized by localized back pain and incidental radicular pain, which lasts from several months to 1 year; the second stage is the progressive stage, which is characterized by rapid neurological decline due to nerve compression and lasts for 2 to 8 weeks. There were some published case reports about primary spinal epidural DLBCL ([Table 1](#T0001){ref-type="table"}).[@CIT0005]--[@CIT0007]Table 1Published case reports about primary spinal epidural diffuse large B-cell lymphomaFirst author and yearPatientLocationThe first manifestationPathologyLiu SZ et al, 2018[@CIT0005]A 43-year-old maleT5Complete paralysisDLBCLCórdoba-Mosqueda et al, 2017[@CIT0006]A 45-year old maleT3An anterior spinal syndrome with hypoesthesia and loss of thermalgesiaDLBCLJagtap SA et al, 2013[@CIT0007]A 32‐year‐old femaleT3‐T4Pain at the level of left infra mammary regionDLBCL

For patients with high suspicion of PSEL, MRI is helpful for diagnosis. MRI plain scan usually showed T1W1 signal or low signal, T2WI signal or high signal, but some literature reported that T2WI showed low signal, may be related to the relative density of tumor cells. Hyperintense T2 signal greater than that of adjacent fat with adjacent expansile bone disease differentiates epidural metastases from lymphoma.[@CIT0008]

Primary spinal epidural non-Hodgkin's lymphoma (NHL) accounts for less than 1% of all NHL.[@CIT0005] Most epidural lymphomas are moderately and well-differentiated B-cell lymphoma. DLBCL is the most common type, accounting for 1.8% of all DLBCL. Pathological examination revealed atypical lymphocyte proliferation, and immunohistochemistry showed positive cluster of differentiation (CD)20, negative leukocyte common antigen and CD138, CD30 and CD3.

The specific management has not been established yet. Surgery is the mainstay of treatment for cord decompression with aggressive chemotherapy in conjunction with radiotherapy is associated with good functional outcome.[@CIT0009] It is not known whether preventive intrathecal injection is necessary. In this case, the patient refused to take preventive intrathecal injection.

All in all, PSEL should be suspected in patients with spinal cord compression with imaging showing isointense, homogeneous extradural contiguous level compressive soft-tissue lesion without bony involvement and previous history of cancer.
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